{"id":5174,"date":"2024-02-02T12:34:07","date_gmt":"2024-02-02T12:34:07","guid":{"rendered":"https:\/\/www.value-dx.eu\/?p=5174"},"modified":"2024-04-22T12:34:30","modified_gmt":"2024-04-22T12:34:30","slug":"value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2","status":"publish","type":"post","link":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/","title":{"rendered":"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections"},"content":{"rendered":"\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-jzkylawd-ba86e75d702405f62001a756eb35483d\">\n.avia-section.av-jzkylawd-ba86e75d702405f62001a756eb35483d{\nbackground-color:#08b4a0;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_1'  class='avia-section av-jzkylawd-ba86e75d702405f62001a756eb35483d main_color avia-section-default avia-no-border-styling  avia-builder-el-0  el_before_av_section  avia-builder-el-first  avia-bg-style-parallax container_wrap fullsize'  ><div class='container av-section-cont-open' ><main  role=\"main\" itemprop=\"mainContentOfPage\"  class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-5174'><div class='entry-content-wrapper clearfix'>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-kx4q0z2f-232d9a2ef875862c0019b3570ef74bf7\">\n#top .av-special-heading.av-kx4q0z2f-232d9a2ef875862c0019b3570ef74bf7{\npadding-bottom:10px;\n}\nbody .av-special-heading.av-kx4q0z2f-232d9a2ef875862c0019b3570ef74bf7 .av-special-heading-tag .heading-char{\nfont-size:25px;\n}\n.av-special-heading.av-kx4q0z2f-232d9a2ef875862c0019b3570ef74bf7 .av-subheading{\nfont-size:15px;\n}\n<\/style>\n<div  class='av-special-heading av-kx4q0z2f-232d9a2ef875862c0019b3570ef74bf7 av-special-heading-h3 blockquote modern-quote modern-centered  avia-builder-el-1  el_before_av_codeblock  avia-builder-el-first  av-linked-heading'><h3 class='av-special-heading-tag '  itemprop=\"headline\"  >VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections<\/h3><div class=\"special-heading-border\"><div class=\"special-heading-inner-border\"><\/div><\/div><\/div>\n\n<\/div><\/div><\/main><!-- close content main element --><\/div><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-1cjng-9db903d36b325f87b66fb9ba7e96614e\">\n.avia-section.av-1cjng-9db903d36b325f87b66fb9ba7e96614e{\nbackground-color:#1b7ca4;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_2'  class='avia-section av-1cjng-9db903d36b325f87b66fb9ba7e96614e main_color avia-section-default avia-no-border-styling  avia-builder-el-3  el_after_av_section  el_before_av_section  avia-bg-style-scroll container_wrap fullsize'  ><div class='container av-section-cont-open' ><div class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-5174'><div class='entry-content-wrapper clearfix'>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-k0i4yzrj-318dd765ad6f41d2fe86b741f8548ed0\">\n.flex_column.av-k0i4yzrj-318dd765ad6f41d2fe86b741f8548ed0{\nborder-radius:0px 0px 0px 0px;\npadding:50px 5% 50px 5%;\n}\n<\/style>\n<div  class='flex_column av-k0i4yzrj-318dd765ad6f41d2fe86b741f8548ed0 av_one_full  avia-builder-el-4  el_before_av_one_fifth  avia-builder-el-first  first flex_column_div  '     ><section  class='av_textblock_section av-yfjs-bdca154287e84706a717077d4cd17983 '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock'  itemprop=\"text\" ><p><span style=\"font-weight: 400;\">Antimicrobial resistance (AMR) poses a significant global health threat, exacerbated by the irrational use of antibiotics, particularly in the treatment of respiratory tract infections in community care. Rapid Point-of-Care Tests (POCTs) can help mitigate overuse, but their adoption remains limited in most European countries. This <\/span><a href=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/12\/Steigenberger_2023_Diagnostics_BarriersFacilitatorsPricingFundingPolicies.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">VALUE-Dx paper<\/span><\/a><span style=\"font-weight: 400;\"> explores the barriers and facilitators within health technology assessment (HTA), pricing, and funding policies that impact the use of POCTs for acute respiratory tract infections in outpatient practices.<\/span><\/p>\n<p><b>Results<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Expert interviews were conducted with representatives from five European countries: Austria, Estonia, France, Poland, and Sweden. The interviews provided comprehensive insights into HTA, funding, and pricing policies in the peri-launch phase. Barriers identified included a lack of evidence for diagnostics, limited transferability methods from medicines to diagnostics, and the absence of price regulation for studied diagnostics. Weak purchasing power due to regional procurement processes was also noted as a pricing-related obstacle. On the funding front, the coverage (reimbursement) of diagnostic tests and optimized remuneration for physicians were recognized as facilitators.<\/span><\/p>\n<p><b>Conclusion<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Diverse barriers and facilitators in the peri-launch phase for POCT uptake were identified, largely influenced by the country context and healthcare system. While the complex HTA process posed challenges, it wasn&#8217;t a barrier to POCT use in most countries.Free pricing was prevalent in all investigated countries, with substantial differences in funding for POCT application. Optimizing funding emerged as a key factor in increasing POCT uptake. Policymakers need to recognize that the non-adoption of peri-launch policies can impose long-term costs on the healthcare system and leave untapped potentials in pricing and funding. Measures against AMR should be integrated, acknowledging the interaction and impact of different policies. The implementation of national action plans against AMR can indirectly influence POCT uptake by addressing barriers related to funding.<\/span><\/p>\n<p><a href=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/12\/Steigenberger_2023_Diagnostics_BarriersFacilitatorsPricingFundingPolicies.pdf\" target=\"_blank\" rel=\"noopener\"><b>Read the paper here<\/b><\/a><b>.\u00a0<\/b><\/p>\n<\/div><\/section><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-3b8mw-b506a38e8d00a7f4906eea669cebc6be\">\n.flex_column.av-3b8mw-b506a38e8d00a7f4906eea669cebc6be{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-3b8mw-b506a38e8d00a7f4906eea669cebc6be av_one_fifth  avia-builder-el-6  el_after_av_one_full  el_before_av_one_fifth  first flex_column_div av-zero-column-padding  column-top-margin'     ><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-2lzlw-3d25ff9ce16d4f57844d3b5b4e0627c5\">\n.flex_column.av-2lzlw-3d25ff9ce16d4f57844d3b5b4e0627c5{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-2lzlw-3d25ff9ce16d4f57844d3b5b4e0627c5 av_one_fifth  avia-builder-el-7  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  column-top-margin'     ><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-7tlo-f8416bb2afc61a4a130355b19410e269\">\n.flex_column.av-7tlo-f8416bb2afc61a4a130355b19410e269{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-7tlo-f8416bb2afc61a4a130355b19410e269 av_one_fifth  avia-builder-el-8  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  column-top-margin'     ><div  class='av-social-sharing-box av-k0i4kjks-6d3450111d8e25130dca06d4190760bd av-social-sharing-box-minimal  avia-builder-el-9  avia-builder-el-no-sibling  av-social-sharing-box-fullwidth'><div class=\"av-share-box\"><ul class=\"av-share-box-list noLightbox\"><li class='av-share-link av-social-link-twitter avia_social_iconfont' ><a target=\"_blank\" aria-label=\"Share on X\" href='https:\/\/twitter.com\/share?text=VALUE-Dx%20paper%20on%20barriers%20and%20facilitators%20in%20pricing%20and%20funding%20policies%20of%20European%20countries%20impacting%20the%20use%20of%20point-of-care%20diagnostics%20for%20acute%20respiratory%20tract%20infections&#038;url=https:\/\/www.value-dx.eu\/?p=5174' data-av_icon='\ue932' data-av_iconfont='entypo-fontello'  title='' data-avia-related-tooltip='Share on X'><span class='avia_hidden_link_text'>Share on X<\/span><\/a><\/li><li class='av-share-link av-social-link-linkedin avia_social_iconfont' ><a target=\"_blank\" aria-label=\"Share on LinkedIn\" href='https:\/\/linkedin.com\/shareArticle?mini=true&#038;title=VALUE-Dx%20paper%20on%20barriers%20and%20facilitators%20in%20pricing%20and%20funding%20policies%20of%20European%20countries%20impacting%20the%20use%20of%20point-of-care%20diagnostics%20for%20acute%20respiratory%20tract%20infections&#038;url=https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/' data-av_icon='\ue8fc' data-av_iconfont='entypo-fontello'  title='' data-avia-related-tooltip='Share on LinkedIn'><span class='avia_hidden_link_text'>Share on LinkedIn<\/span><\/a><\/li><li class='av-share-link av-social-link-mail avia_social_iconfont' ><a  aria-label=\"Share by Mail\" href='mailto:?subject=VALUE-Dx%20paper%20on%20barriers%20and%20facilitators%20in%20pricing%20and%20funding%20policies%20of%20European%20countries%20impacting%20the%20use%20of%20point-of-care%20diagnostics%20for%20acute%20respiratory%20tract%20infections&#038;body=https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/' data-av_icon='\ue805' data-av_iconfont='entypo-fontello'  title='' data-avia-related-tooltip='Share by Mail'><span class='avia_hidden_link_text'>Share by Mail<\/span><\/a><\/li><\/ul><\/div><\/div><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-1gk3g-e035d72a73a93486e640208771f4a074\">\n.flex_column.av-1gk3g-e035d72a73a93486e640208771f4a074{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-1gk3g-e035d72a73a93486e640208771f4a074 av_one_fifth  avia-builder-el-10  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  column-top-margin'     ><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-yzdo-63e3a9df4e270ed0fd52b6929706fb26\">\n.flex_column.av-yzdo-63e3a9df4e270ed0fd52b6929706fb26{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-yzdo-63e3a9df4e270ed0fd52b6929706fb26 av_one_fifth  avia-builder-el-11  el_after_av_one_fifth  avia-builder-el-last  flex_column_div av-zero-column-padding  column-top-margin'     ><\/div><\/div><\/div><\/div><!-- close content main div --><\/div><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-k0i590fy-427634ed8909a6d2106239c938ad0962\">\n.avia-section.av-k0i590fy-427634ed8909a6d2106239c938ad0962{\nbackground-color:#1b7ca4;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_3'  class='avia-section av-k0i590fy-427634ed8909a6d2106239c938ad0962 main_color avia-section-default avia-no-border-styling  avia-builder-el-12  el_after_av_section  avia-builder-el-last  avia-bg-style-scroll container_wrap fullsize'  ><div class='container av-section-cont-open' ><div class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-5174'><div class='entry-content-wrapper clearfix'>\n\n<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":152,"featured_media":4733,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-5174","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections - value-dx<\/title>\n<meta name=\"description\" content=\"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections - value-dx\" \/>\n<meta property=\"og:description\" content=\"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/\" \/>\n<meta property=\"og:site_name\" content=\"value-dx\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-02T12:34:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-22T12:34:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1421\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Leandra\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ValueDx\" \/>\n<meta name=\"twitter:site\" content=\"@ValueDx\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Leandra\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/\"},\"author\":{\"name\":\"Leandra\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#\\\/schema\\\/person\\\/9da693a7844518fa62482abe916eba8d\"},\"headline\":\"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections\",\"datePublished\":\"2024-02-02T12:34:07+00:00\",\"dateModified\":\"2024-04-22T12:34:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/\"},\"wordCount\":1419,\"image\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/shutterstock_1714915966-scaled.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/\",\"name\":\"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections - value-dx\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/shutterstock_1714915966-scaled.jpg\",\"datePublished\":\"2024-02-02T12:34:07+00:00\",\"dateModified\":\"2024-04-22T12:34:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#\\\/schema\\\/person\\\/9da693a7844518fa62482abe916eba8d\"},\"description\":\"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/shutterstock_1714915966-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/shutterstock_1714915966-scaled.jpg\",\"width\":2560,\"height\":1421},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/homepage\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/\",\"name\":\"value-dx\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.value-dx.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#\\\/schema\\\/person\\\/9da693a7844518fa62482abe916eba8d\",\"name\":\"Leandra\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/author\\\/leandra\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections - value-dx","description":"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/","og_locale":"en_US","og_type":"article","og_title":"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections - value-dx","og_description":"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.","og_url":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/","og_site_name":"value-dx","article_published_time":"2024-02-02T12:34:07+00:00","article_modified_time":"2024-04-22T12:34:30+00:00","og_image":[{"width":2560,"height":1421,"url":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg","type":"image\/jpeg"}],"author":"Leandra","twitter_card":"summary_large_image","twitter_creator":"@ValueDx","twitter_site":"@ValueDx","twitter_misc":{"Written by":"Leandra","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#article","isPartOf":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/"},"author":{"name":"Leandra","@id":"https:\/\/www.value-dx.eu\/#\/schema\/person\/9da693a7844518fa62482abe916eba8d"},"headline":"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections","datePublished":"2024-02-02T12:34:07+00:00","dateModified":"2024-04-22T12:34:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/"},"wordCount":1419,"image":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/","url":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/","name":"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections - value-dx","isPartOf":{"@id":"https:\/\/www.value-dx.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#primaryimage"},"image":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg","datePublished":"2024-02-02T12:34:07+00:00","dateModified":"2024-04-22T12:34:30+00:00","author":{"@id":"https:\/\/www.value-dx.eu\/#\/schema\/person\/9da693a7844518fa62482abe916eba8d"},"description":"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.","breadcrumb":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#primaryimage","url":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg","contentUrl":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg","width":2560,"height":1421},{"@type":"BreadcrumbList","@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.value-dx.eu\/index.php\/homepage\/"},{"@type":"ListItem","position":2,"name":"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections"}]},{"@type":"WebSite","@id":"https:\/\/www.value-dx.eu\/#website","url":"https:\/\/www.value-dx.eu\/","name":"value-dx","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.value-dx.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.value-dx.eu\/#\/schema\/person\/9da693a7844518fa62482abe916eba8d","name":"Leandra","url":"https:\/\/www.value-dx.eu\/index.php\/author\/leandra\/"}]}},"jetpack_featured_media_url":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/posts\/5174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/users\/152"}],"replies":[{"embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/comments?post=5174"}],"version-history":[{"count":0,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/posts\/5174\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/media\/4733"}],"wp:attachment":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/media?parent=5174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/categories?post=5174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/tags?post=5174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}